Bifogade filer
PDF
Kurs
+1,94%
Likviditet
0,08 MSEK
Kalender
| Est. tid* | ||
| 2025-05-21 | N/A | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2025-05-20 | N/A | Årsstämma |
| 2025-05-20 | 08:40 | Kvartalsrapport 2025-Q1 |
| 2025-02-25 | - | Bokslutskommuniké 2024 |
| 2024-12-17 | - | Extra Bolagsstämma 2024 |
| 2024-11-19 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-27 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-21 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-20 | - | Bokslutskommuniké 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-24 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2023-05-23 | - | Årsstämma |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2022-05-10 | - | Årsstämma |
| 2022-05-10 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-29 | - | Extra Bolagsstämma 2022 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-20 | - | Split SYNT 1:10 |
| 2021-05-12 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-02 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
| 2020-07-14 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-05 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-14 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-30 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
| 2019-04-29 | - | Årsstämma |
| 2019-04-29 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2018-04-25 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2017-11-10 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2017-04-25 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-10-28 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-27 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2016-04-26 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-10-30 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-13 | - | Årsstämma |
| 2015-04-13 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-17 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2015-02-13 | - | Bokslutskommuniké 2014 |
| 2014-11-28 | - | Kvartalsrapport 2014-Q3 |
| 2014-09-26 | - | Extra Bolagsstämma 2014 |
| 2014-08-29 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
SyntheticMR announced today that they have received their EU Medical Device Regulation (MDR) certificate. This is a necessary step to continue to provide the European market with SyMRI 12.1 after May 2024. With this new certificate, SyntheticMR will also be able to release new products on the European market, which are significantly different from already existing products, such as SyMRI 3D.
The EU MDR regulate the worldwide production as well as the distribution of medical devices on the EU market. The MDR replaces MDD that was the former directive requirements for medical devices in the EU, with higher requirements on safety and performance. The MDR has existed since March 2017 and the QA/RA and R&D teams at SyntheticMR has since then, put a lot of work into implementing the new MDR regulations. "This has been one of my biggest goals and one of my top priorities during my four years at SyntheticMR. We have finally reached this goal" says Madeleine Enström, Quality Assurance and Regulatory Affairs Manager at SyntheticMR AB.
For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com orMadeleine Enström, Quality Assurance and Regulatory Affairs Manager, +46 13 101 650 madeleine.enstrom@syntheticmr.com (hege.nabo@syntheticmr.com)